Pink Agenda | Search

临床试验

计划入组 60 人 · 首次发布于 2013 年 3 月 4 日

已完成

NCT03792425

Clinical Evaluation of Pink Esthetic Score

计划入组 16 人 · 首次发布于 2019 年 1 月 3 日

尚未招募

NCT07024953

The Agenda-Setting for Kidney Disease Trial

计划入组 108 人 · 首次发布于 2025 年 6 月 17 日

药物

查看全部 283 →

Small Molecule

Approved

Bismuth subsalicylate(Diphen, Kaopectate Reformulated Aug 2006, Kola-pectin, Pepto-bismol, Percy Medicine)

相关疾病：Diarrhea, Dyspepsia，另有 8 项

C₇H₅BiO₄

Small Molecule

Approved

Alpelisib(Piqray 300 Mg Daily Dose, Vijoice 50 Mg 28 Day, Piqray)

相关疾病：HR+, HER2-, Advanced Breast Cancer, PIK3CA-Related Overgrowth Spectrum (PROS)，另有 1 项

C₁₉H₂₂F₃N₅O₂S

Biotech

Approved

Salmon, unspecified

机构

查看全部 124 →

PINK PEARLS INC

United States

MiNK Therapeutics

United States

BeCare Link, LLC

United States

资讯

查看全部 654 →

去年

Advances in Metastatic Breast Cancer Treatment Extend Lives and Improve Quality of Life

去年

FDA Advisory Committee Skeptical of Stealth BioTherapeutics' Barth Syndrome Drug Application

去年

临床试验

Pink and Dude Chef

Clinical Evaluation of Pink Esthetic Score

The Agenda-Setting for Kidney Disease Trial

药物

Bismuth subsalicylate(Diphen, Kaopectate Reformulated Aug 2006, Kola-pectin, Pepto-bismol, Percy Medicine)

Alpelisib(Piqray 300 Mg Daily Dose, Vijoice 50 Mg 28 Day, Piqray)

Salmon, unspecified

机构

PINK PEARLS INC

MiNK Therapeutics

BeCare Link, LLC

资讯

Advances in Metastatic Breast Cancer Treatment Extend Lives and Improve Quality of Life

FDA Advisory Committee Skeptical of Stealth BioTherapeutics' Barth Syndrome Drug Application

Palatin Technologies Completes $1.1M Public Offering Following OTC Pink Transition